• The document is an intimation and enclosed presentation for an analyst meet scheduled to be held from 27th May 2026 to 29th May 2026.
  • The purpose of the event is to present a strategic and business update, as detailed in the enclosed investor presentation deck.
  • The presentation was made available on the company's website at https://www.indegene.com/.
  • The disclosure is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
  • The letter is signed by Srishti Ramesh Kaushik, Company Secretary and Compliance Officer.

Presentation Financial & Business Highlights

The enclosed investor presentation provides the following key financial and operational updates:

Financial Performance (FY26):

  • Revenue: INR 35,105 Million
  • Adjusted EBITDA Margin: 19.4%
  • Revenue CAGR (FY21–FY26): 29.4%
  • Operating Cash Flow to PAT Ratio: 162%
  • Revenue Per Employee: $74.7K
  • PAT CAGR (FY21-FY26): 16.7%
  • Zero debt balance sheet.

Client Metrics:

  • Active Client Relationships: 91 (up from 44 in FY21)
  • Clients with >$1M revenue: 53 (up from 22 in FY21)
  • Serves 20 of the Top 20 global life sciences companies.
  • Net Revenue Retention (NRR): >100% every year.
  • Top-20 Client Revenue: INR 25.2k Mn in FY26 (3.0x growth from FY21's INR 8.3k Mn).

Strategic Positioning & Outlook:

  • Company positions itself as an AI-embedded, domain-deep operating partner for life sciences.
  • The FY27 pipeline is stated to be 17% higher than at the same point last year.
  • Recent M&A acquisitions (Cult, Trilogy, Biopharm, Warn and Cake Communications) are highlighted as adding capabilities and local credibility.
  • The presentation outlines a large structural market opportunity, estimating the outsourced life sciences operations spend to grow significantly from 2024 to 2030.
  • It details the company's strategy to capture wallet share from traditional agencies and CROs by leveraging AI and centralized, platform-based delivery models.

Operational Capabilities & Efficacy Claims:

The presentation lists end-to-end capabilities across Clinical Development, Medical Affairs, PV & Regulatory Affairs, Commercial Operations, and Patient Engagement, citing numerous efficacy improvements for clients, including:

  • 50% reduction in enrollment costs
  • 40% reduction in study setup time
  • 65% faster submissions
  • 60-70% improvement in cost efficiency
  • 50% reduction in time-to-market for campaigns
  • 65%+ savings compared to traditional AORs

Additional Notes Section

  • The disclosure includes an enclosure: the Investor Presentation | May 2026.
  • The document contains extensive financial data, business metrics, and strategic commentary from the enclosed presentation.
  • The tone of the disclosure is neutral and compliant, serving as a formal intimation of the event and presentation.